What is LY trial?
The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) was a randomized trial designed to compare two fixed doses of dabigatran, each administered in a blinded manner, with open-label use of warfarin in patients who had atrial fibrillation and were at increased risk for stroke.
What are the long term effects of Pradaxa?
PRADAXA increases the risk of bleeding and can cause significant and, sometimes, fatal bleeding. Promptly evaluate any signs or symptoms of blood loss (e.g., a drop in hemoglobin and/or hematocrit or hypotension). Discontinue PRADAXA in patients with active pathological bleeding.
Why is Pradaxa not used?
Pradaxa should not be used to prevent valve thrombosis or thromboembolism (e.g., stroke, myocardial infarction, systemic embolism, prosthetic mechanical valve thrombosis, and vascular death) in patients with mechanical prosthetic heart valves.
Does Pradaxa cause heart problems?
The researchers found Pradaxa was associated with an increased risk of heart attack or acute coronary syndrome (heart attack or angina), compared with two other commonly used blood thinners, warfarin (Coumadin, Jantoven) and enoxaparin (Lovenox).
What is the generic for Pradaxa?
There is currently no generic for Pradaxa (dabigatran), so it can be expensive, even with insurance.
Can you have a stroke while on Pradaxa?
PRADAXA lowers your chance of having a stroke by helping to prevent clots from forming. If you stop taking PRADAXA, you may have increased risk of forming a clot in your blood.
How is dabigatran used in the RE-LY trial?
The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) was a randomized trial designed to compare two fixed doses of dabigatran, each administered in a blinded manner, with open-label use of warfarin in patients who had atrial fibrillation and were at increased risk for stroke.
What was the purpose of the RE-LY trial?
Trial Design. The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) was a randomized trial designed to compare two fixed doses of dabigatran, each administered in a blinded manner, with open-label use of warfarin in patients who had atrial fibrillation and were at increased risk for stroke.
Is there a stroke risk reduction with Pradaxa?
Pradaxa [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc. 2. Connolly SJ, Walletin L, Yusuf S. Additional events in the RE‑LY trial [Letter to the Editor]. N Engl J Med. 2014;371 (15):1464-1465. 3. Data on file. Boehringer Ingelheim Pharmaceuticals, Inc. 4. Andersen KK, Olsen TS, Dehlendorff C, Kammersgaard LP.